GT Biopharma, Inc.
GT Biopharma, Inc. (GTBP) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · GTBP · as of Jun 8, 2026
Key Statistics
Explore GT Biopharma, Inc. Data
gtbp stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 5 · Buy rate: 80.0%
Competitors & Peers
gtbp competitorsGTBP
ARTL
CARM
DRMA
LIPO
PBMStock Performance
Full HistoryAbout GT Biopharma, Inc.
GT Biopharma, Inc. a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE…
what is gt biopharma, inc. · gtbp stock overview · gt biopharma, inc. company profile · who is gt biopharma, inc. ceo · gtbp NASDAQ · gt biopharma, inc. headquarters · gt biopharma, inc. business segments
About Stock Overview & Key Data
GT Biopharma, Inc. (GTBP) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 27, 2018. As of the latest trading session, GTBP stock price is $0.44, with a market capitalization of $4.7M. The stock has returned -85.47% over the past 12 months and -44.10% year-to-date.
According to 5 Wall Street analysts, the consensus rating for GT Biopharma, Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, GT Biopharma, Inc. reported revenue of — and net income of -$28.4M. For detailed data — including GT Biopharma, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, GT Biopharma, Inc. (GTBP) stock price is $0.44. The stock is traded on NASDAQ under the ticker symbol GTBP. The 52-week range is $0.26 – $3.85.